跳至主要内容
临床试验/NCT03647852
NCT03647852招募中不适用

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Children's Hospital of Fudan University3 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2019年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
150
试验地点
3
主要终点
sustained abdominal pain relief

研究概览

简要总结

IgA vasculitis is relatively common in children,especially in Asian countries. Abdominal manifestation could be severe, including bleeding, pancreatitis,appendicitis and intestinal intussusception. Delayed diagnosis could be fatal and cause severe complications.Nowadays no guidelines for those with severe abdominal manifestations in China.However, the most used treatment is steroid. For those severe forms are methylprednisolone pulse, IVIG, immunosuppressants and blood purification. Given the fact that different strategies lead to different endings which varies in cost, adverse effect and clinical outcomes in different medical centers, it is necessary to give birth to a useful and feasible strategy. This clinical trial is a muti-center, randomized,controlled prospective study.Patients with gastrointestinal disease will be recruited in three children's medical centres in Shanghai and will be randomized to two groups: MP group and IVIG group. Cost effect and clinical outcomes will be evaluated. Blood purification will be evaluated as a remedy when MP and IVIG fail to cure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • both genders
  • age between 2-16 years old
  • IgA vasculitis with gastrointestinal involvement
  • course of disease less than 2 months
  • refractory to ordinary dosage of prednisolone (less than 2mg/kg/d)

排除标准

  • patients with severe sepsis
  • patients with central nervous system infection,
  • patients with severe pneumonia
  • patients with chronic infection (such as EBV, CMV, Tuberculosis)
  • patients complicated by CKD who need renal replacement therapy
  • patients suffering from severe central nervous system complications as intracranial hemorrhage or neuropathy

研究组 & 干预措施

Methylprednisolone group

Experimental

In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)

干预措施: Methylprednisolone (Drug)

Methylprednisolone group

Experimental

In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)

干预措施: other basic supportive treatment (Drug)

IVIG group

Active Comparator

In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)

干预措施: IVIG (Drug)

IVIG group

Active Comparator

In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)

干预措施: other basic supportive treatment (Drug)

结局指标

主要结局

sustained abdominal pain relief

时间窗: 3 days after treatment

no abdominal pain complaint and no abdominal tenderness

次要结局

  • hypertension(7 days after treatment)
  • The number of days in hospital(at the time of discharge)
  • sustained abdominal pain relief(7 days after treatment)
  • the number of days of taking fasting(At the time of discharge)
  • steroid-related diabetes(3 days after treatment)
  • cost of treatment(4 weeks after treatment)
  • other treatment rather than assigned intervention(4 weeks after treatment)
  • Drug-related side effects(3 days after treatment)
  • tolarable food type(2 weeks after treatment)
  • infection(4 weeks after treatment)
  • ocular hypertension(7 days after treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验